TL;DR
The reshoring story this stretch split cleanly into three ledgers. The pharma tariff's rate ladder went fully live on September 29 and immediately produced its first conversion — Bayer's $2.2B Ohio plant — while the macro data showed the factory-construction boom plateauing and rotating from shells into data centers. In semis, the equity market is pricing options, not groundbreakings: Intel rallied 30% in a month on an unconfirmed memory rumor while TSMC, the company actually converting US capacity into record margins, weighs a second campus in Texas.
The pharma tariff is now a machine for converting duties into dirt — with a three-day proof point
The Section 232 regime stopped being a threat and became an operative price list, and the market's first response arrived almost instantly. The full ladder — 100% default on patented drugs down to 0% for companies with a "qualifying onshoring plan agreement" — took effect September 29, and Bayer announced its $2.2B New Albany, Ohio plant on October 2, three days later: its first North American pharma manufacturing site and Ohio's largest-ever international healthcare project Pharma Reshoring: Section 232 Goes Fully Live
+1.
"This investment is about one thing - it's about bringing manufacturing closer to the patients we serve."
— Bayer COO Sebastian Guth, via Ohio Governor's office
The caveat that keeps the skeptic honest: Genentech's $750M Hillsboro groundbreaking (September 28) was made under Roche's pre-existing three-year tariff exemption, not in response to the 100% rate — and, as the trade press put it, "$750 million has bought format capacity with nothing yet assigned to it" Pharma Reshoring+1. The revenue conversion is a 2030s story (Bayer's modules: 2031 and 2034), so none of this touches equipment vendors' order books yet — which is why Thermo Fisher and Danaher's Q3 prints in late October remain the real test of the $480B pledge wave.
What to watch: Which companies file for the 20%/0% onshoring-bargain rates — the Commerce filings are now the regime's own ledger of committed US capex.
The construction boom rotated: factory shells plateaued, and data centers carry everything
The Census C30 data delivered the first monthly increase in manufacturing construction since January — but it's a floor, not a recovery. Manufacturing construction sits at $170.7B SAAR, still down 19.2% year over year, while data center spending jumped 7.5% in the month alone and is up 73% over twelve months US Manufacturing Construction: First Monthly Increase Since January
.
"Frankly, it's becoming difficult to contextualize the size and speed of this boom."
— Anirban Basu, ABC chief economist, via Construction Dive
This confirms the composition shift the prior digest flagged: the investable action is inside the buildings — equipment, fit-out, power — not in new shells, which favors the electrical and specialty-contractor names over any "factory construction" trade. The squeeze is real on both sides: ISM prices paid surged to 77.9 on oil above $100, even as the PMI itself hit 54.5, a ninth straight month of expansion ISM at 54.5
. A 5.24% 10-year Treasury raises the hurdle rate on every remaining greenfield project — exactly when announced plants get quietly re-scoped.
What to watch: Whether ISM prices paid holds above 75 in the October print, and whether Eaton-style price increases keep sticking against it.
In semis, the market pays for options; the margins belong to TSMC
The semiconductor reshoring trade has bifurcated into two different assets wearing the same label. Intel is at $119.33, up 30.2% in a month, on a $630.8B market cap with a trailing-twelve-month net margin of −19.8% — pricing the possibility that SK hynix takes memory capacity at Ohio One, a deal that remains unconfirmed and un-denied Intel Rallies 30% in a Month on the Ohio Memory Option
.
"A confirmed agreement to manufacture memory at Intel's Ohio fab would give the long-delayed facility a clear purpose and a revenue stream."
— TradingNews, via the Intel market view
TSMC, meanwhile, is the company actually earning from US capacity — 49.9% net margin, four straight beats — and is now weighing a Texas campus with fabs at $20B+ each on top of its $265B Arizona commitment, reportedly contingent on Congress extending the 35% manufacturing tax credit TSMC Mulls Multibillion-Dollar Texas Site. The Forbes scorecard quantifies the announced-vs-built gap across the whole story: "$11 trillion investment announcements vs $232 billion in new foreign direct investment" — with Intel's Ohio plant (announced 2022) now targeted for 2030–31 and Micron's New York groundbreaking two years late Forbes. The durable winners remain the purchase-order names building all of it.
What to watch: Intel's Q3 earnings in late October — whether the Ohio memory option firms up or the 30% re-rating has to survive on foundry fundamentals alone.
What surprised us
- The tariff regime timed its own proof point. Bayer's announcement landing three days after full implementation is either the best-planned press release in pharma or the cleanest demonstration yet that the rate ladder is doing exactly what it was designed to do Pharma Reshoring+1.
- The biggest mover isn't responding to the tariff at all. Roche/Genentech is building against an exemption it already secured — meaning the headline groundbreakings partly reflect pre-tariff bargains, not the new regime's leverage Pharma Reshoring+1.
- Manufacturing demand is real and cost pressure is real, simultaneously. Nine straight months of ISM expansion alongside prices paid at war-time highs (77.9) means the reshoring order books are growing into a squeeze — the margin question for the equipment names is now genuinely two-sided ISM at 54.5.
- A $630B market cap on a rumor. Intel's +30% month on an unconfirmed, un-denied lease talks is the sharpest evidence yet that reshoring equities trade on options and headlines while the actual groundbreaking ledger (Intel Ohio: 2030–31) moves at decade speed Intel Rallies 30%.
Open threads worth a vote
Who Actually Wins from Reshoring — Delta Edition
Since last time
- Promoted — Macro construction data. Last cycle this was a passing flag (the composition shift toward fit-out over shells, a Treasury-rate aside). It's now a full section: Census C30 numbers, the ISM cost squeeze, and the data-center rotation.
- Escalated — The pharma tariff, from a framework (the 20% bargain rate as an observable ledger) to a machine with its first conversion: Bayer's $2.2B Ohio plant three days after full implementation. Intel/Ohio escalated from a SK hynix non-denial watch item to a 30% equity re-rating on the unconfirmed rumor. TSMC escalated from an Arizona counterpoint to a potential second US campus in Texas — now an open thread.
- Demoted — SK hynix. The Ohio One question survives only as the unconfirmed rumor propping up Intel's rally. The Indiana packaging groundbreaking ($4B+, $458M CHIPS, 2H 2029), the Korea Herald cost-logic quote, and the ~$26B Korean fab approvals are all gone from this briefing.
- Disappeared — GlobalFoundries, entirely. Last cycle's centerpiece refutation of the reshoring equity premium (CHIPS money + government equity + Singapore expansion) appears nowhere in the new briefing, and its GFS earnings open thread is gone with it. Also dropped: the IEEPA durability note (Section 232 surviving the Supreme Court ruling), the zero-duty specialty-category channel detail, and TSMC's Arizona 2H 2027 pull-forward (Arizona's $265B commitment survives as context).
- Unchanged — The core test: equipment vendors' Q3 order books vs. the $480B pledge wave, and Commerce filings as the regime's own ledger of committed US capex. If you internalized that last time, it's the same watch, now with a date attached (late October).
The pharma tariff is now a machine for converting duties into dirt — with a three-day proof point (Escalated)
Last time the story was the rate ladder's fine print; this time it's the first conversion. The full ladder — 100% default on patented drugs down to 0% for companies with a "qualifying onshoring plan agreement" — took effect September 29, and Bayer announced its $2.2B New Albany, Ohio plant on October 2, three days later: its first North American pharma manufacturing site and Ohio's largest-ever international healthcare project Pharma Reshoring: Section 232 Goes Fully Live+1.
"This investment is about one thing - it's about bringing manufacturing closer to the patients we serve."
— Bayer COO Sebastian Guth, via Ohio Governor's office
The caveat that keeps the skeptic honest: Genentech's $750M Hillsboro groundbreaking (September 28) was made under Roche's pre-existing three-year tariff exemption, not in response to the 100% rate — and, as the trade press put it, "$750 million has bought format capacity with nothing yet assigned to it" Pharma Reshoring+1. The revenue conversion is a 2030s story (Bayer's modules: 2031 and 2034), so none of this touches equipment vendors' order books yet — which is why Thermo Fisher and Danaher's Q3 prints in late October remain the real test of the $480B pledge wave.
What to watch: Which companies file for the 20%/0% onshoring-bargain rates — the Commerce filings are now the regime's own ledger of committed US capex.
The construction boom rotated: factory shells plateaued, and data centers carry everything (Promoted)
This is the newest material. The Census C30 data delivered the first monthly increase in manufacturing construction since January — but it's a floor, not a recovery. Manufacturing construction sits at $170.7B SAAR, still down 19.2% year over year, while data center spending jumped 7.5% in the month alone and is up 73% over twelve months US Manufacturing Construction: First Monthly Increase Since January.
"Frankly, it's becoming difficult to contextualize the size and speed of this boom."
— Anirban Basu, ABC chief economist, via Construction Dive
This confirms the composition shift the prior digest flagged: the investable action is inside the buildings — equipment, fit-out, power — not in new shells, which favors the electrical and specialty-contractor names over any "factory construction" trade. The squeeze is real on both sides: ISM prices paid surged to 77.9 on oil above $100, even as the PMI itself hit 54.5, a ninth straight month of expansion ISM at 54.5. A 5.24% 10-year Treasury raises the hurdle rate on every remaining greenfield project — exactly when announced plants get quietly re-scoped.
What to watch: Whether ISM prices paid holds above 75 in the October print, and whether Eaton-style price increases keep sticking against it.
In semis, the market pays for options; the margins belong to TSMC (Escalated)
The SK hynix watch item from last cycle has become an equity story. Intel is at $119.33, up 30.2% in a month, on a $630.8B market cap with a trailing-twelve-month net margin of −19.8% — pricing the possibility that SK hynix takes memory capacity at Ohio One, a deal that remains unconfirmed and un-denied Intel Rallies 30% in a Month on the Ohio Memory Option.
"A confirmed agreement to manufacture memory at Intel's Ohio fab would give the long-delayed facility a clear purpose and a revenue stream."
— TradingNews, via the Intel market view
TSMC, meanwhile, is the company actually earning from US capacity — 49.9% net margin, four straight beats — and is now weighing a Texas campus with fabs at $20B+ each on top of its $265B Arizona commitment, reportedly contingent on Congress extending the 35% manufacturing tax credit TSMC Mulls Multibillion-Dollar Texas Site. The Forbes scorecard quantifies the announced-vs-built gap across the whole story: "$11 trillion investment announcements vs $232 billion in new foreign direct investment" — with Intel's Ohio plant (announced 2022) now targeted for 2030–31 and Micron's New York groundbreaking two years late Forbes. The durable winners remain the purchase-order names building all of it.
What to watch: Intel's Q3 earnings in late October — whether the Ohio memory option firms up or the 30% re-rating has to survive on foundry fundamentals alone.
What surprised us
- The tariff regime timed its own proof point. Bayer's announcement landing three days after full implementation is either the best-planned press release in pharma or the cleanest demonstration yet that the rate ladder is doing exactly what it was designed to do Pharma Reshoring+1. [NEW]
- The biggest mover isn't responding to the tariff at all. Roche/Genentech is building against an exemption it already secured — meaning the headline groundbreakings partly reflect pre-tariff bargains, not the new regime's leverage Pharma Reshoring+1. [NEW]
- Manufacturing demand is real and cost pressure is real, simultaneously. Nine straight months of ISM expansion alongside prices paid at war-time highs (77.9) means the reshoring order books are growing into a squeeze — the margin question for the equipment names is now genuinely two-sided ISM at 54.5. [NEW]
- A $630B market cap on a rumor. Intel's +30% month on an unconfirmed, un-denied lease talks is the sharpest evidence yet that reshoring equities trade on options and headlines while the actual groundbreaking ledger (Intel Ohio: 2030–31) moves at decade speed Intel Rallies 30%. [UPDATED — sharpens last cycle's GFS "AI-optics stock" surprise into a market-wide claim]
Open threads
- Closed/absorbed: Last cycle's Section 232 uptake thread (who takes the 20% bargain) is now the body of the pharma section — Bayer is the first data point, and the Commerce filing list remains the observable test.
- Dropped: The GFS earnings thread (Malta vs. Singapore) disappeared along with the GlobalFoundries section. If you were tracking it, the briefing no longer is.
- Live now: